UnitedHealth Group Incorporated UNH
Composite 48/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 24/100 — a strong mark against it.
Income ranks 75/100 — a moderate point in its favour. Momentum ranks 66/100 — a moderate point in its favour. Valuation ranks 64/100 — a moderate point in its favour.
Growth ranks 24/100 — a strong mark against it. Quality ranks 32/100 — a moderate mark against it.
What the company does UnitedHealth Group Incorporated (UNH) operates through four segments: Optum Health (care delivery and management), Optum Insight (software and advisory services), Optum Rx (pharmacy care services), and UnitedHealthcare (health benefit plans and services). The company serves employers, payers, providers, and public-sector entities, focusing on integrated healthcare delivery and financial services.
Key financials UNH reports ROE 14.1%, ROA 4.4%, and ROCE 8.0%. Gross, operating, and net margins stand at 19.5%, 7.1%, and 3.1%, respectively. Revenue growth is 0.4%, while EPS growth is 61.5%. Debt/Equity is 0.69, with a current ratio of 0.78 and interest coverage of 5.52x.
Stock health The stock shows mixed signals: 6-month momentum is strong at 38.11%, but 12-month performance is 33.05% with a 14.66% drawdown from the 52-week high. RSI(14) is 38.10, indicating neither overbought nor oversold conditions. The Sidaravia score is 53.5, with Strength (59.1) and Momentum (66.5) outperforming Quality (49.8) and Growth (43.8).
Price vs fair value UNH trades at a discount of 20.60% versus the analyst mean target of 475.23. - Governance and cybersecurity lawsuits raise risk perceptions (Simply Wall St., 2026-08-18). - Dividend appeal is compared unfavorably to Eli Lilly (Insider Monkey, 2026-08-19). - Forward P/E of 20.66 and PEG of 0.42 suggest valuation support relative to growth.
Looking forward Forward P/E of 20.66 and PEG of 0.42 imply valuation support, while revenue growth of 0.4% and net margins of 3.1% highlight execution challenges. Analysts emphasize governance and cybersecurity risks as key watchpoints.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.